A new gold-based drug slows tumor growth by 82% in animals and targets cancer cells more precisely than chemotherapy.

A new gold-based drug can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

Scientists at Weill Cornell Medicine have uncovered a critical mechanism driving the growth of treatment-resistant prostate ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

In a new review, Arizona State University researchers, working with colleagues around the world, explore how established ...

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

Severe infection with Covid-19 has been found to produce a powerful cancer-fighting cell that can shrink tumors.

Instead of repressing tumor-suppressor genes, this form of EZH2 drives rapid protein production and activates growth factors like TGF-β, fostering an environment around the tumor that promotes cancer ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...